Story perspectives

Bayer Faces €3.76 Billion Loss Amid Roundup Settlement

3/4/2026

Summary

Story summary

Bayer AG reported a fourth-quarter loss of 3.76 billion euros.
The loss stems from high litigation costs and weak pharmaceutical and consumer-health sales.
Bayer proposed a nationwide settlement related to Roundup claims, potentially costing up to 7.25 billion dollars over 21 years.
Bayer's 2026 outlook includes core earnings per share (EPS) of 4.30–4.80 euros and adjusted EBITDA of 9.6–10.1 billion euros.
The Stockholders' Meeting is scheduled for April 24, 2026.

1 of 1

Story summary

Bayer AG reported a fourth-quarter loss of 3.76 billion euros.
The loss stems from high litigation costs and weak pharmaceutical and consumer-health sales.
Bayer proposed a nationwide settlement related to Roundup claims, potentially costing up to 7.25 billion dollars over 21 years.
Bayer's 2026 outlook includes core earnings per share (EPS) of 4.30–4.80 euros and adjusted EBITDA of 9.6–10.1 billion euros.
The Stockholders' Meeting is scheduled for April 24, 2026.